Effects of vitamin D supplementation on metabolic and endocrine parameters in PCOS: a randomized-controlled trial

• DOI: 10.1007/s00394-018-1760-8
• Publication Date: 2018-06-26T10:38:13Z
• Authors: Christian Trummer; Verena Schwetz; Martina Kollmann; Monika Wölfler; Julia Münzker; Thomas R. Pieber; Stefan Pilz; Annemieke C. Heij...; Barbara Obermayer...; Elisabeth Lerchbaum
• Keywords: Adult; Blood Glucose; Original Contribution; Vitamins; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Double-Blind Method; Austria; Dietary Supplements; Humans; Insulin; Female; Insulin Resistance; Vitamin D; Cholecalciferol; Polycystic Ovary Syndrome

Vitamin D status may be associated with insulin resistance and other key features of polycystic ovary syndrome (PCOS), but data from preliminary randomized controlled trials (RCTs) are conflicting. Therefore, we aimed to investigate the effects vitamin supplementation on plasma glucose area under curve (AUCgluc, primary outcome measure) metabolic endocrine parameters (secondary measures). This study was a single-center, double-blind, placebo-controlled trial conducted between December 2011 July 2017 at Medical University Graz, Austria. One-hundred eighty women PCOS 25-hydroxyvitamin [25(OH)D] concentrations < 75 nmol/L were in 2:1 ratio either receive 20,000 IU cholecalciferol weekly or placebo over 24 weeks. Primary between-group difference AUCgluc end while adjusting for baseline values. In total, 123 participants completed [age 25.9 ± 4.7 years; BMI 27.5 7.3 kg/m2; 25(OH)D 48.8 16.9 nmol/L, fasting 84 8 mg/dL]. lead significant increase [mean treatment effect 33.4 nmol/L; 95% confidence interval (CI) 24.5 42.2; p 0.001] had no (mean − 9.19; CI 21.40 3.02; = 0.139). Regarding secondary measures, observed decrease 60 min during oral tolerance test 10.2 mg/dL; 20.2 0.3; 0.045). exception reduced OGTT.